AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 17.83 |
| Open | 18.07 |
| Bid | 17.72 x 800 |
| Ask | 17.77 x 800 |
| Day's Range | 17.62 - 18.19 |
| 52 Week Range | 11.95 - 26.10 |
| Volume | 131,066 |
| Avg. Volume | 755,850 |
| Market Cap | 609.382M |
| Beta (3Y Monthly) | -0.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.16 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 20.38 |
- Simply Wall St.•7 days ago
Estimating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
Does the December share price for AMAG Pharmaceuticals Inc (NASDAQ:AMAG) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
- GlobeNewswire•8 days ago
Study of Feraheme demonstrates Improvements in Fatigue and Quality Of Life in Iron Deficiency Anemia Patients
The ASH poster presentation focused on the durability of the improvements in several patient reported outcomes (PRO) measures in patients with iron deficiency anemia (IDA) following a single course of ferumoxytol (2 x 510 mg, 3-8 days apart) over a 6-month extension study period. In the initial phase 3 trial, patients treated with ferumoxytol showed improvement in quality of life compared to placebo as measured by fatigue-related symptoms.
GuruFocus.com•12 days agoPaul Tudor Jones Continues to Buy Apple, Alibaba
Guru increased holdings of these 7 stocks
- GlobeNewswire•12 days ago
AMAG Pharmaceuticals Awards Four Grants to Further Research in Preterm Birth and Preeclampsia
WALTHAM, Mass., Nov. 29, 2018 -- As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG.
- Zacks•15 days ago
AMAG's Label Expansion of Lead Products Raises Share Price
AMAG's (AMAG) label expansion efforts for Feraheme and Makena are encouraging.
- GlobeNewswire•last month
Detailed Research: Economic Perspectives on KB Home, Lennox International, CorVel, Acorda Therapeutics, PROS, and AMAG Pharmaceuticals — What Drives Growth in Today's Competitive Landscape
NEW YORK, Nov. 08, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Thomson Reuters StreetEvents•last month
Edited Transcript of AMAG earnings conference call or presentation 1-Nov-18 12:00pm GMT
Q3 2018 AMAG Pharmaceuticals Inc Earnings Call
- GlobeNewswire•last month
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 06, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that company management will participate in the following investor conferences:.
- Zacks•last month
AMAG Posts Wider-Than-Expected Q3 Loss, Beats on Revenues
AMAG reports wider than expected loss in the third quarter of 2018. The company completed the sale of Cord Blood Registry in August 2018.
- Motley Fool•last month
Here's Why AMAG Pharmaceuticals Tumbled 12.7% Today
The company's third-quarter financials did little to inspire confidence that its sales can withstand the launch of generic competition.
Motley Fool•last monthAMAG Pharmaceuticals Inc (AMAG) Q3 2018 Earnings Conference Call Transcript
AMAG earnings call for the period ending September 30, 2018.
- Zacks•last month
AMAG Pharmaceuticals (AMAG) Reports Q3 Loss, Tops Revenue Estimates
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 0.00% and 3.88%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
AMAG Pharmaceuticals: 3Q Earnings Snapshot
On a per-share basis, the Waltham, Massachusetts-based company said it had profit of 89 cents. Losses, adjusted for one-time gains and costs, were 77 cents per share. The results met Wall Street expectations. ...
- GlobeNewswire•last month
AMAG Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Achieved strong third quarter financial performance and increased full year 2018 guidance Acquired AMAG-423 for severe preeclampsia, reaffirming the.
- Zacks•last month
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
- Zacks•2 months ago
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings
We take a look at a few stocks that might deliver an earnings beat when they report next week.
- Zacks•2 months ago
AMAG Pharmaceuticals (AMAG) Q3 Earnings Preview: What to Watch Ahead of the Release
AMAG Pharmaceuticals (AMAG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, November 1, 2018 at 8:00 a.m. ET
WALTHAM, Mass., Oct. 25, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2018 financial results will be released on Thursday, November.
- GlobeNewswire•2 months ago
Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•2 months ago
Is the Options Market Predicting a Spike in AMAG Pharmaceuticals (AMAG) Stock?
Investors need to pay close attention to AMAG Pharmaceuticals (AMAG) stock based on the movements in the options market lately.
- Zacks•2 months ago
New Strong Sell Stocks for October 5th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Market Realist•2 months agoMakena Auto Injector Is a Key Asset for Antares Pharma in 2018
In Q2 2018, partner Amag Pharmaceuticals (AMAG) reported revenues of $105.2 million for Makena, which is a year-over-year (or YoY) rise of 2.43%. According to Antares Pharma’s Q2 2018 conference call, this growth was driven mainly by the increased overall uptake of the product coupled with the launch of the Makena auto injector in the US market in March 2018. As per AMAG Pharmaceuticals’ estimates based on distributor dispensing data and physician market research data from its investor presentation, Makena accounted for a 51% share of the total market for preventing pre-term birth in at-risk women.
Market Realist•2 months agoAntares Pharma Could Report Solid Revenue Growth in Fiscal 2018
In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%. The revenue growth was mainly driven by a 27% YoY rise in product sales, which reached $22.04 million in H1 2018. Wall Street analysts expect Antares Pharma to report revenues of $59.56 million in fiscal 2018, which is a YoY rise of 9.25%.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals and Endoceutics Announce Presentation at the 2018 Annual Meeting of The North American Menopause Society on the Effect of Time Since Menopause, Age and Previous Hormone Therapy on the Response to Intravaginal Prasterone
AMAG Pharmaceuticals, Inc. (AMAG) and Endoceutics today announced an oral presentation regarding the effect of time since menopause, age, and previous hormone therapy on treatment efficacy of intravaginal 6.5 mg prasterone (INTRAROSA®) at the Annual Meeting of The North American Menopause Society (NAMS) in San Diego, California. David F. Archer, M.D., NCMP, will present the study results on Thursday, October 4th from 5:15 PM to 5:30 PM. Dr. Archer and colleagues analyzed combined data obtained from two prospective, randomized, double-blind, placebo-controlled clinical trials to evaluate the effect of daily intravaginal 6.5 mg INTRAROSA administered for 12 weeks to women who identified moderate to severe pain at sexual activity (dyspareunia) as their most bothersome symptom (MBS) of vulvar and vaginal atrophy, or VVA.
- Zacks•2 months ago
AMAG In-Licenses Global Rights to Orphan Drug Candidate
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
